Lifelong follow-up is recommended for all high-risk patients (every patient with a germline mutation, PGL, young age <20 years, large tumor size ≥5–6 cm, for SDHB carriers tumor size ≥3–3.5 cm, multiplicity/recurrence, noradrenergic/dopaminergic phenotype at the initial presentation, moderately to poorly differentiated PCC according to the GAPP classification system). Here, SDHB is linked to neoplasm.